U.S. SEVERE ORAL MUCOSITIS MARKET ANALYSIS

U.S. Severe Oral Mucositis Market, By Drug Type (Palifermin, Amifostine, Chlorhexidine, Sucralfate, Late Phase (Avasopasem and Dusquetide)), By Cause (Chemotherapy and Radiotherapy), By Grade (Grade III and Grade IV), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Published In : Aug 2021
Code : CMI4571
Pages :116
Formats :
Excel and PDF
Industry : Pharmaceutical

U.S. Severe Oral Mucositis MarketSize and Trends

The U.S. Severe oral mucositis Market is estimated to be valued at US$ 78.5 Mn in 2021 and is expected to exhibit a CAGR of 19.2% during the forecast period (2021-2028).

The increasing prevalence of head and neck cancer is a primary driving factor for the growth of the U.S. severe oral mucositis market over the forecast period. According to the American Society of Clinical Oncology (ASCO)’s 2021 report, approximately 4% of individuals suffered from head and neck cancer in the U.S. and an estimate of 66,630 people (48,740 men and 17,890 women) were expected to develop head and neck cancer.